Description: OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
Home Page: oncozenge.com
Gustavslundsvägen 34
Bromma,
167 51
Sweden
Phone:
46 8 31 14 20
Officers
| Name | Title |
|---|---|
| Mr. Stian Kildal | Chief Executive Officer |
| Mr. Michael Owens B.A., B.S., B.S.B.A | Chief Financial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5615 |
| Price-to-Sales TTM: | 1067.6293 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |